Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test that could spot kidney trouble in diabetes?

NCT ID NCT07773467

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at whether routine blood test markers—like the Systemic Immune-Inflammation Index and platelet ratios—can help identify diabetic kidney disease in people with type 2 diabetes. Researchers will compare these markers across patients with different levels of albuminuria (a sign of kidney damage) and healthy controls. The goal is to find a simple, cost-effective way to detect and track this common complication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No drug or intervention is being tested. This observational study analyzes routine blood test markers (Systemic Immune-Inflammation Index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and platelet indices) as potential biomarkers.
What this could lead to
If these blood markers prove reliable, they could offer a simple, low-cost way to detect diabetic kidney disease earlier and monitor its progression.
What could go wrong
This is an observational study, so it can't prove cause and effect. The markers may not be specific enough to distinguish diabetic kidney disease from other conditions, and results may not generalize beyond this patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 18 to 80 years diagnosed with type 2 diabetes mellitus attending Assiut University Hospitals, categorized based on urinary albumin-to-creatinine ratio (uACR) into normoalbuminuria, microalbuminuria, and macroalbuminuria, alongside healthy control subjects.

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 80 years, both males and females. * Confirmed clinical diagnosis and history of Type 2 Diabetes Mellitus (T2DM). * Healthy control subjects matched for age and sex (for the control cohort). Exclusion Criteria: * Type 1 diabetes mellitus. * Acute infections or clinical signs of active inflammation at the time of sampling. * Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus). * Known or recently diagnosed malignancies. * Chronic liver diseases, including cirrhosis or hepatitis. * Nephrotic syndrome or other known non-diabetic kidney diseases. * History of immunosuppressive therapy, systemic corticosteroids, or cytotoxic medications within the past 3 months prior to enrollment. * Pregnancy. * Significant cardiovascular complications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Albuminuria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Albuminuria diabetic kidney disease proteinuria type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Albuminuria Diabetic kidney disease Diabetic nephropathies Type 2 diabetes mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.